"Somatic POLE mutation and ultra-hypermutated genotype in a de novo hig" by Daniel Mundt, Isaac Melguizo-Gavilanes et al.
 

Somatic POLE mutation and ultra-hypermutated genotype in a de novo high-grade, isocitrate dehydrogenase wild-type glioma: Treatment implications

Abstract

Pembrolizumab leads to a durable response in ultra-hypermutated, high-grade, glioma.

Type

Article

PubMed ID

38237101


 

Share

COinS